



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration  
Silver Spring, MD 20993

DMF 039173

**DMF ACKNOWLEDGEMENT**

SUNPURE EXTRACTS PVT. LTD.  
ATTN:  
E-25, INDUSTRIAL AREA  
SIKANDRABAD (U.P.) 203205, INDIA

Dear Mr. Sir,

The Food and Drug Administration acknowledges receipt of the following Drug Master File (DMF) submission:

<b><u>DMF NUMBER ASSIGNED:</u></b>	039173
<b><u>DATE OF SUBMISSION:</u></b>	NOVEMBER 20, 2023
<b><u>DMF TYPE:</u></b>	II
<b><u>SUBJECT (TITLE):</u></b>	COLEUS FORSKOHLII EXTRACT 98%
<b><u>HOLDER:</u></b>	SUNPURE EXTRACTS PVT. LTD.
<b><u>SUBMITTED BY:</u></b>	SUNPURE EXTRACTS PVT. LTD.

All subsequent correspondence to this DMF should be identified with the information as provided above.

Your DMF will be reviewed only in connection to a New Drug Application, Abbreviated New Drug Application, Investigational New Drug Application, Biological License Application, New Animal Drug Application, Abbreviated New Animal Drug Application, Investigational New Animal Drug Application, or DMF it is intended to support when a Letter of Authorization (LOA) is submitted to the DMF and a copy of the LOA is submitted in the application e.g., NDA, that references the DMF.

For information on various DMF submissions, example of letter templates and DMF Guidance for Industry, check the DMF website at <https://www.fda.gov/drugs/forms-submission-requirements/drug-master-files-dmfs>

The holder of the DMF is responsible for compliance with 21 CFR314.420 as interpreted in “The Guideline for Drug Master Files” at <https://www.fda.gov/drugs/drug-master-files-dmfs/guideline-drug-master-files-dmf>

You are expected to:

- Adhere to the statement of commitment you have provided.
- Provide the following submissions to the DMF: